To the full analysis
Aurobindo Pharma stock: valuation and P/E
AUROPHARMA.NSAurobindo Pharma trades at a P/E of 26.1 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 16.5).
Daily figure as of 13 Nov 2026
P/E
26.1
P/S
2.8
P/B
2.74
PEG
1.87
P/E on expected earnings
The forward P/E of 20.6 divides the price by the earnings per share that 21 analysts expect on average for the next twelve months: $0.93. The twelve months are made up pro rata of the estimates for fiscal 2027 and 2028.
20.6
P/E on fiscal 2027
22.5
on estimated fiscal 2027 earnings ($0.85 per share)
P/E on fiscal 2028
19.5
on estimated fiscal 2028 earnings ($0.98 per share)
Analysts mostly estimate adjusted earnings, excluding amortization of acquisitions and other one-off items. The estimates change all the time; they are no promise and no price target.
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
26.1
Median of prior years
16.5
Reading
pricier than usual
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2017 | 17.2 |
| 2018 | 14.3 |
| 2019 | 19.6 |
| 2020 | 8.5 |
| 2021 | 9.7 |
| 2022 | 14.8 |
| 2023 | 15.7 |
| 2024 | 20.6 |
| 2025 | 19 |
| 2026 | 21.6 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Apr 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.